Briefing Summary: US FDA Posts Advisory Committee Materials for Titan Pharmaceuticals’ Probuphine Implant– JAN 12, 2016 (PDAC)

The US FDA has posted details, including company and FDA Briefing Materials, for the Psychopharmacologic Drugs Advisory Committee (PDAC) meeting on Tuesday, January 12, 2016. The Committee will discuss new drug application (NDA) 204442 for Probuphine (buprenorphine hydrochloride and ethylene vinyl acetate) subdermal implant, submitted by Braeburn Pharmaceuticals, Inc. (Braeburn), on behalf of Titan Pharmaceuticals, for the proposed indication of maintenance treatment of opioid dependence.

See the SAC Tracker report